Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1994-03-02
1996-04-02
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514643, 514912, A61K 31205, A61K 3114
Patent
active
055041132
ABSTRACT:
A formulation and method includes an acceptable drug, such as Prostaglandins, Flurbiprofen, Keterolac Tromethamine, Cetirizine HCl Indomethacin and Bufrolin, which are interactive with benzalkonium chloride to form a precipitate along with benzalkonium chloride acting as a preservative and an amino acid having enough positive charge at the pH of the formulation and/or Tromethamine present in an amount sufficient to interfere with the interaction between the drug and benzalkonium chloride in order to maintain the preservative activity of the benzalkonium chloride. Further, the use of Lysine, L-arginine, or Histidine is also useful in reducing the cytotoxicity of the formulation.
REFERENCES:
Chemical Abstracts, 110:219120 (1989). Fu et al.
Allergan Inc.
Fay Zohreh
Hackler Walter A.
LandOfFree
Enhancement of benzalkonium chloride preservative activity in fo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of benzalkonium chloride preservative activity in fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of benzalkonium chloride preservative activity in fo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2016613